In a large survey of 31 cancer centres in Africa, those surveyed expressed concerns over the limited access to taxane chemotherapy and aromatase inhibitors, the absence of access to targeted therapy, the unavailability of radiation therapy and a lack of in-house pathology services [22]. This evidence concerns the gene CYP19A1 and cancer.